Papillomatous Anogenital Lesions in a Patient With Human Immunodeficiency Virus

**QUESTION**

A 45-year-old African American man with history of human immunodeficiency virus (HIV) presented to the office complaining of a rash in his right groin for the past 7 weeks. He had a history of nonadherence to his combination antiretroviral therapy (cART), and at a previous visit, his HIV-1 load was noted to be >10 000 000 copies/mL. After that visit, the patient became adherent with his cART regimen. He presented to his primary care physician’s office 3 weeks later, reporting a lesion in his right groin, and was treated with doxycycline for possible skin and soft-tissue infection. Blood work performed 2 weeks later showed an HIV-1 viral load of 1604 copies/mL. The patient was seen in the infectious disease clinic and reported that the rash had only gotten worse. He described it as “itchy but not painful.” He denied fevers, chills, night sweats, unexplained weight loss, nausea, vomiting, and diarrhea.

At physical examination, the patient appeared well developed and well nourished. No oropharyngeal thrush was seen at oral examination. Findings of neurological, cardiovascular, respiratory, and abdominal examination were also unremarkable. Skin examination revealed multiple exophytic masses in the right inguinal and perineal areas, the largest measuring about 3 cm in diameter, and areas of hypopigmentation (Figure 1). There was no associated erythema or tenderness to palpation. The CD4+ cell count was 59/μL, and the HIV load, 733 copies/mL. The patient was referred to dermatology for biopsy. What is your diagnosis?

**Figure 1.** Images of the primary exophytic mass and associated lesions. Left: Right inguinal 3-cm exophytic mass marked in purple, with adjacent visible areas of hypopigmentation. Right: Elevation of scrotum revealing more areas of hypopigmentation and additional exophytic lesions in the right scrotum, medial thigh, and perineal area, each measuring about 1 cm in diameter.
Papillomatous Anogenital Lesions in a Patient With Human Immunodeficiency Virus

Diagnosis: Verrucous herpes infection.

Two 4-mm punch biopsy specimens were taken from the patient’s right thigh exophytic mass, one for histopathologic examination and one for tissue culture (marked in purple in Figure 1). Hematoxylin-eosin staining at scanning magnification showed verrucous hyperplasia with focal epidermal necrosis and acantholysis (Figure 2). Higher magnification at ×400 revealed multinucleated epithelial cells with nuclear molding, consistent with herpes virus. Immunohistochemical staining was performed and was focally positive for herpes simplex virus (HSV) and negative for treponema. Final tissue culture results were negative for all aerobic, fungal, and acid-fast bacilli positive organisms. Taken together, the diagnosis of verrucous HSV was confirmed.

Treatment was then started with acyclovir, 400 mg 3 times daily for 14 days. The patient’s condition improved after treatment, although he reported difficulty with compliance. The patient was then started on valacyclovir, 1000 mg twice daily.

Two months later, he presented with resolution of the exophytic masses and residual hypopigmented skin changes at the site of the original lesions (Figure 3). Procedural intervention was not required.

HSV is commonly transmitted by different routes and can affect various areas of the body, most frequently the orofacial and genital regions. The prevalence of HSV-2 serotype is even higher among individuals with human immunodeficiency virus (HIV), particularly those living in North America [1]. Genital infections typically present with grouped, shallow vesicles that cause significant pain and discomfort. They often last 8–10 days before spontaneously regressing [2]. In persons living with HIV, the clinical presentation of HSV infections can vary widely. Depending on the patient’s immune status, HSV infections may last even longer and manifest more aggressively than they would in an immunocompetent patient [3, 4].

A subset of HSV- and HIV-coinfected patients develop verrucous growths, and the pathophysiology of these lesions is not...
completely understood [5–9]. The papillomatous lesions seen in our patient is a representative case of such atypical manifestations. It may be secondary to immune reconstitution inflammatory syndrome (IRIS) after the initiation of combination antiretroviral therapy (cART). In another proposed mechanism, HIV infection causes dendritic cells to produce antiapoptotic cytokines that create an environment favorable to tissue proliferation [5].

The appearance of warty, papillomatous lesions is often consistent with the presentation of condyloma acuminata, typically a manifestation of human papilloma virus (HPV) serotypes 6 and 11. Differential diagnosis for this type of clinical presentation may also include condyloma lata from secondary syphilis, lichen planus, and cancers such as squamous cell carcinoma, secondary to cancerous HPV serotypes. Like HSV infection, several of the causes leading to similar-appearing lesions, such as those caused by HPV, are more common in patients with HIV [10–12]. This highlights the importance of a broad differential diagnosis and appropriately inclusive testing.

Smith et al [6] first described the appearance of verrucous, hyperkeratotic lesions secondary to HSV infection in patients with HIV, suggesting that an increased presence of factor XIIIa–positive dendritic cells in these cases may be related to the pathogenesis of this presentation. Tong and Mutasim [5] later described a clinical presentation suggestive of condyloma acuminata in a patient with HIV. Further investigation revealed the absence of detectable HPV serotypes and the presence of HSV infection that was responsive to acyclovir treatment. Similar clinical presentations of HSV in individuals with HIV have been described elsewhere, although these cases have not always been responsive to medical therapy alone [7–9]. In such events, resection of the lesions is required in addition to acyclovir therapy.

The severe, atypical presentation of HSV in our patient was most consistent with IRIS due to viral shedding after the initiation of cART [13–16]. IRIS develops in approximately 16% of persons living with HIV who start antiretroviral therapy, which is called “unmasking” when occurring in the context of a previously unrecognized opportunistic infection and “paradoxical” when the opportunistic infection was previously recognized and being treated [17–20]. The rapid immune response after treatment initiation may cause a systemic or local inflammatory reaction, which can specifically target the sites of initial infection. Our patient had started cART only 3 weeks before presentation with new lesions. Hence, we propose that the verrucous
HSV in this case was most likely a manifestation of HSV IRIS. The patient's cART was continued, and the underlying infection was treated with acyclovir, leading to a resolution of his symptoms.

**Note**

**Potential conflicts of interest.** I. B. reports support from Gilead and ViiV for research, paid to their institution, and personal fees for serving on speakers bureaus for Gilead, ViiV, and Janssen, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Omar E. Fernandez,1 Smitha Gudipati,2 Dayoung Ko,3 Alison Boucher,4 and Indira Brar5

1Wayne State University School of Medicine, Detroit, Michigan, USA; 2Department of Infectious Disease, Henry Ford Hospital, Detroit, Michigan, USA; and 3Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA

**References**

1. Kouyoumjian SP, Heijnen M, Chaabna K, et al. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. AIDS 2018; 32:1343–52.
2. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357:1513–8.
3. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol 2007; 57:737–63; quiz 764–6.
4. Thurman AR, Doncel GF. Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention. Int J STD AIDS 2012; 23:613–9.
5. Tong P, Mutasim DF. Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease. Br J Dermatol 1996; 134:797–800.
6. Smith KJ, Skelton HG 3rd, Frissman DM, Angritt P; Military Medical Consortium of Applied Retroviral Research Washington. Verrucous lesions secondary to DNA viruses in patients infected with the human immunodeficiency virus in association with increased factor XIIIa-positive dermal dendritic cells. J Am Acad Dermatol 1992; 27:943–50.
7. Carrasco DA, Trizna Z, Colome-Grimmer M, Tyring SK. Verrucous herpes of the scrotum in a human immunodeficiency virus-positive man: case report and review of the literature. J Eur Acad Dermatol Venereol 2002; 16:511–5.
8. Simonsen M, Nahas SC, Silva Filho EV, Araújo SE, Kiss DR, Nahas CS. Atypical perianal herpes simplex infection in HIV-positive patients. Clinics (Sao Paulo) 2008; 63:143–6.
9. Quesada AE, Gallione S, Colome M, Brown RE. Verrucous herpes of the scrotum presenting clinically as verrucous squamous cell carcinoma: case report and review of the literature. Ann Clin Lab Sci 2014; 44:208–12.
10. Wielden U, Kreuter A. Genital warts in HIV-infected individuals [in German]. Hautarzt 2017; 68:192–8.
11. MudrikoVA T, Jaspers C, Ellerbrok P, Hoepelman A. HPV-related anogenital disease and HIV infection: not always ‘ordinary’ condylomata acuminata. Neth J Med 2008; 66:98–102.
12. Peeling RW, Mabey D, Kamb ML, Chen XS, Radolf JD, Benzaken AS. Syphilis. Nat Rev Dis Primers 2017; 3:17073.
13. Tobian AA, Grabowski MK, Serwadda D, et al; Rakai Health Sciences Program. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013; 208:839–46.
14. Johnston C, Corey L. Current concepts for genital herpes simplex virus infection: diagnostics and pathogenesis of genital tract shedding. Clin Microbiol Rev 2016; 29:149–61.
15. Ford ES, Magaret AS, Spak CW, et al. Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. AIDS 2018; 32:2525–31.
16. Fife KH, Mugwanya K, Thomas KK, et al; Partners in Prevention HSV/HIV Transmission Study Team. Transient increase in herpes simplex virus type 2 (HSV-2)-associated genital ulcers following initiation of antiretroviral therapy in HIV/HSV-2-coinfected individuals. J Infect Dis 2016; 213:1573–8.
17. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; iDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251–61.
18. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361–73.
19. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213–27.
20. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48:101–7.

Correspondence: Smitha Gudipati, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202 (Sgudipa2@hfhs.org).

Clinical Infectious Diseases® **2022**;**75**(1):**159**–**62**

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs license (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

https://doi.org/10.1093/cid/ciab853